Comparing Interest in Thigh Administration of Long-acting Cabotegravir/Rilpivirine Among Hypothetical Users, Early Adopters, and Trial Participants With Experience
We read with interest the article by Ford et al on intramuscular thigh administration of cabotegravir/rilpivirine (CAB/RPV)-long-acting (LA) as part of an interval or rotational treatment strategy for persons with HIV (PWH). 1 LA injectable antiretroviral therapy (ART) has multifaceted clinical and public health benefits for PWH and their communities.This innovation may help overcome challenges to daily oral ART adherence, and has led to virologic suppression in PWH with viremia. 2,3Real-world early adopters
Authors
- Moira McNulty (ORCID: https://orcid.org/0000-0002-9651-254X)
- Jonathan A. Colasanti (ORCID: https://orcid.org/0000-0002-0536-9769)
- Lauren Frances Collins (ORCID: https://orcid.org/0000-0002-0170-5454)
- Katerina A Christopoulos
Institutions
- San Francisco General Hospital (US)
- Emory University (US)
- University of California, San Francisco (US)
- University of California System (US)
- University of Chicago (US)
- Grady Health System (US)
- Global Solutions for Infectious Diseases (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-06-24
- DOI
- https://doi.org/10.1093/cid/ciaf333
- Primary Topic
- Pharmaceutical studies and practices
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Emory University
- National Institutes of Health
- Center for AIDS Research, University of Washington